Nasdaq adds Moderna to Nasdaq-100. Moderna stock gains 1.08 percent
Published on 10/06/2026 at 17:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna Inc. stock was last at EUR 182.82 on Tradegate on October 6, 2026, up 1.08 percent from EUR 180.86, while Nasdaq announced on October 1, 2026 that Moderna will join the Nasdaq-100 before market open on October 9, 2026, according to FinanzNachrichten.de. The index change gives Moderna a defined market event as its oncology pipeline approaches another data milestone.
Nasdaq-100 inclusion sets a date
Nasdaq will replace Warner Bros. Discovery with Moderna in the Nasdaq-100 before the October 9, 2026 market open. The inclusion does not change Moderna's operating results, but it places the biotechnology company in a benchmark tracked by more than 200 investment products, according to the same October 1 announcement from FinanzNachrichten.de.
The timing matters because Moderna has scheduled presentations on its personalized cancer vaccine intismeran autogene at the European Society for Medical Oncology Congress from October 23 to October 27, 2026. Its lead phase 3 melanoma study is set for a Presidential Symposium on October 24, and Moderna will host an investor webcast that day, according to the company's September 21 release published by Moderna.
Revenue remains modest against valuation
Moderna generated USD 145.0 million of revenue in the second quarter of 2026, up 2.00 percent from the second quarter of 2025, and reported a GAAP net loss of USD 782.0 million, or USD 1.97 per diluted share. The figures came from the company's second-quarter earnings discussion reported by Yahoo Finance on October 1, 2026.
Management reiterated a 2026 revenue-growth outlook of up to 10.00 percent and projected year-end cash and investments of USD 4.7 billion to USD 5.2 billion. That outlook makes the upcoming cancer-data presentations important for the valuation debate because current market capitalization stands at USD 76.1 billion as of October 6, 2026.
Citi keeps the valuation debate alive
Citi downgraded Moderna from Neutral to Sell on September 30, 2026, while raising its price target from USD 60.00 to USD 80.00. CNBC reported that analyst Geoff Meacham still saw 60.00 percent downside from the prior US close and argued that the valuation required aggressive oncology sales assumptions.
On Nasdaq, MRNA was last at USD 191.84 at 11:25 a.m. ET on October 6, 2026, down 5.60 percent from USD 203.21. The same quote stood between a 52-week low of USD 22.28 and a 52-week high of USD 212.19, leaving the stock 9.59 percent below its high while the Nasdaq-100 inclusion and ESMO timetable provide two concrete dates for the next valuation test.
Two dates now shape the stock
Tradegate showed Moderna last at EUR 182.82 at 9:10 a.m. CEST on October 6, 2026, up 1.08 percent versus the prior Tradegate close of EUR 180.86 on October 5, 2026. Price source: substitute price Tradegate, Lang & Schwarz without data set. The further course of trading is shown by the continuously updated real-time quote of Moderna stock.
Moderna stock facts
- Company: Moderna, Inc.
- ISIN: US60770K1079
- Ticker: MRNA
- Primary exchange: Nasdaq
- Price substitute Tradegate as of October 6, 2026, 9:10 a.m. CEST: EUR 182.82
- Change versus prior close: plus 1.08 percent
- Prior close Tradegate October 5, 2026: EUR 180.86
- Market capitalization: USD 76.1 billion as of October 6, 2026
- 52-week range: USD 22.28-212.19 as of October 6, 2026
- Sector / Industry: Healthcare / Biotechnology
- Index membership: Nasdaq-100 from October 9, 2026
